Loading...
Living Modified Organism (LMO)
  |  
Decisions on the LMO Risk Assessments  
last updated: 08 May 2020
Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.
Swine influenza virus vaccine
EN
H1N1 NS1
No
The swine influenza vaccine is a bivalent vaccine containing two modified virions, H1N1 and H3N2, for developing immunity to both viruses. The modified H1N1 expresses H1N1 hemagglutinin (HA) and neuraminidase (NA), while the modified H3N2 expresses H3N2 HA and NA proteins. The other eight influenza proteins are from H3N2 for both modified virions. Attenuation was achieved by a truncation in the carboxy end of nonstructural protein 1. The vaccine was created through the transfection of eight plasmids corresponding to each viral genomic segment for each virus (separately). The fractions (H1N1 and H3N2) were later combined to create the vaccine.
EN
The term “Recipient organism” refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas “Parental organisms” refers to those that were involved in cross breeding or cell fusion.
  • BCH-ORGA-SCBD-45782-7 Organism Influenza A virus (Influenza, Flu, Avian flu, Human flu, Swine influenza, Equine influenza, Bird flu)
    Viruses
EN
Characteristics of the modification process
plasmid pHW2000
EN
  • Direct DNA transfer (plasmid-based transfection)
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
  • BCH-GENE-SCBD-45883-4 Hemagglutinin gene | Influenza A virus (Influenza, Flu, Avian flu, Human flu, Swine influenza, Equine influenza, Bird flu)
    Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
  • BCH-GENE-SCBD-115567-3 Nonstructural protein 1 | Influenza A virus (Influenza, Flu, Avian flu, Human flu, Swine influenza, Equine influenza, Bird flu)
    Protein coding sequence
  • BCH-GENE-SCBD-115568-1 Polymerase acidic protein | Influenza A virus (Influenza, Flu, Avian flu, Human flu, Swine influenza, Equine influenza, Bird flu)
    Protein coding sequence
  • BCH-GENE-SCBD-115569-1 Polymerase basic protein 1 | Influenza A virus (Influenza, Flu, Avian flu, Human flu, Swine influenza, Equine influenza, Bird flu)
    Protein coding sequence
  • BCH-GENE-SCBD-115570-1 Polymerase basic protein 2 | Influenza A virus (Influenza, Flu, Avian flu, Human flu, Swine influenza, Equine influenza, Bird flu)
    Protein coding sequence
  • BCH-GENE-SCBD-115571-1 Nucleoprotein | Influenza A virus (Influenza, Flu, Avian flu, Human flu, Swine influenza, Equine influenza, Bird flu)
    Protein coding sequence
  • BCH-GENE-SCBD-115573-1 Neuraminidase | Influenza A virus (Influenza, Flu, Avian flu, Human flu, Swine influenza, Equine influenza, Bird flu)
    Protein coding sequence
  • BCH-GENE-SCBD-115574-1 Matrix protein 1 | Influenza A virus (Influenza, Flu, Avian flu, Human flu, Swine influenza, Equine influenza, Bird flu)
    Protein coding sequence
  • BCH-GENE-SCBD-115572-1 Matrix protein 2 | Influenza A virus (Influenza, Flu, Avian flu, Human flu, Swine influenza, Equine influenza, Bird flu)
    Protein coding sequence
  • BCH-GENE-SCBD-115575-2 Nuclear export protein | Influenza A virus (Influenza, Flu, Avian flu, Human flu, Swine influenza, Equine influenza, Bird flu)
    Protein coding sequence
  • BCH-GENE-SCBD-115580-1 Bovine growth hormone terminator | Bos taurus - Cow, Cattle, Bull, Auroch, Oxen, Bullocks
    Terminator
  • BCH-GENE-SCBD-103749-1 Human Cytomegalovirus promoter | Human betaherpesvirus 5 (Human cytomegalovirus, HCMV, HHV-5)
    Promoter
  • BCH-GENE-SCBD-115581-2 Human polymerase 1 promoter | Homo sapiens (HUMAN)
    Promoter
  • BCH-GENE-SCBD-115582-2 Polymerase I terminator | Mus musculus (Mouse, House mouse, MOUSE)
    Terminator
Transcription
Eight expression plasmids (pHW2000) corresponding to the viral genomic segments were transfected to express all influenza genes. The first eight genetic constructs above are for the H1N1 fraction and the later 8 are for the H3N2 fractions of the vaccine. The plasmid contains bidirectional sets of expression cassettes: Cytomegalovirus promoter - Bovine growth hormone terminator (sense) and Human polymerase I promoter - Mus musculus polymerase I terminator (antisense). The combination of transcription in both directions and interaction with host cellular machinery results in the production of infectious virions.

For protein expression of the influenza genes, transcription by RNA polymerase II is directed from the Cytomegalovirus promoter and terminates at the bovine hormone terminator. For segments VII and VII (matrix protein 2 and nuclear export protein, respectively), the transcripts will be spliced to join the initial coding sequences to the later sequences and form a mature mRNA. The transcripts receive 5' caps and 3' poly-adenylated tails. Thus, the transcripts are translated into proteins. To produce viral RNA to function as genomic material, transcription must produce negative sense (antisense) cRNA. Thus, transcription is directed from the human polymerase I promoter and terminates at the Mus musculus polymerase I terminator. These transcripts have a 5' triphosphate group and no polyadenylated tail. Thus, they are not translated into proteins.

Sequence source
H1N1 modified virion (Lot no. 241-192) - first eight genetic constructs above
Influenza strain A/swine/Minnesota/37866/1999 (H1N1): HA and NA proteins

Influenza strain A/Swine/Texas/4199-2/98 (H3N2): PB1, PB2, PA, NP, M1, M2, NS1 and NEP

H3N2 modified virion (Lot no. 241-196) - later eight genetic constructs above
Influenza strain A/Swine/Texas/4199-2/98 (H3N2): PB1, PB2, PA, HA, NP, NA, M1, M2, NS1 and NEP

Note:
For both modified virions, the nonstructural protein 1 (NS1) has been carboxyl-truncated and codes for amino acids 1 to 126 of the native protein. The truncation is related to the attenuation (reduction in virulence) of the seed virus.
EN
LMO characteristics
EN
  • Vaccine
Detection method(s)
EN
Records referencing this document Show in search
Record type Field Record(s)
Country's Decision or any other Communication LMO identification 1
Risk Assessment generated by a regulatory process Living modified organism(s) 1